10-Q: InMed Pharma Reports Q1 Loss, Going Concern Warning

InMed Pharmaceuticals Inc. reported an increased net loss for Q1 2026, alongside a going concern warning and a significant legal dispute impacting its commercial segment.

Summary

• InMed Pharmaceuticals Inc. reported a net loss of $1.73 million for the three months ended September 30, 2025, an increase from $1.68 million in the same period last year.
• The company's cash, cash equivalents, and short-term investments stood at $9.4 million as of September 30, 2025, expected to fund operations into Q4 2026.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year.
• Commercial segment sales (BayMedica) decreased by 11% to $1.12 million, primarily due to lower product pricing driven by increased competition.
• Research and development expenses for the Pharma segment decreased by 17% to $0.58 million.
• Two new directors, Neil Klompas and John Bathery, were appointed to the board in October 2025.
• BayMedica is involved in a legal arbitration seeking approximately $3.4 million in past royalty payments and $2.3 million in future annual minimum payments, which could materially impact the company if unfavorable.

Sentiment

Score: 3

Explanation: The sentiment is negative due to an increased net loss, declining commercial sales and gross profit, and a formal 'going concern' warning. A significant legal dispute adds further uncertainty and potential financial burden. While R&D expenses decreased and new board members were appointed, these positives are overshadowed by the financial challenges and operational risks.

Positives

• Net loss per share improved significantly to $(0.44) from $(2.71) due to a higher weighted average of outstanding common shares.
• Cash used in operating activities decreased to $1.61 million from $1.83 million in the prior year period.
• Research and development expenses for the Pharma segment decreased by 17% ($0.1 million) due to lower external contractors and research supplies.
• Interest and other income increased by 65% to $93,765, driven by higher average cash on hand.
• Appointment of two experienced directors, Neil Klompas (healthcare/biotechnology) and John Bathery (pharmaceutical industry, corporate development), strengthens the board.
• Preclinical data for INM-901 (Alzheimer's disease program) was presented at a leading scientific conference, indicating ongoing R&D progress.
• Phase 2 clinical trial for INM-755 (Epidermolysis Bullosa) showed a positive indication of enhanced anti-itch activity, and the company is pursuing strategic partnerships for this candidate.

Negatives

• Net loss increased to $1.73 million from $1.68 million in the prior year period.
• Commercial segment sales decreased by 11% to $1.12 million, primarily due to lowering product pricing in response to increased competition.
• Gross profit decreased by 18% to $403,159.
• General and administrative expenses for the Commercial segment increased by 59% due to higher salaries, employee benefits, and marketing expenses.
• The company used cash in financing activities ($0.14 million) compared to providing cash in the prior year ($0.84 million).
• An inventory write-down due to obsolescence of $208,737 was recorded as of September 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year, requiring additional capital to finance operations.
• The company's future viability is dependent on its ability to raise additional capital through equity, debt, collaborations, or other strategic transactions, which may not be available on acceptable terms or at all.
• The outcome of the Patent License Matter arbitration with a third-party licensor, seeking approximately $3.4 million in past payments and $2.3 million in future annual minimum payments, could have a material adverse impact on the company's business and financial condition.
• The commercial viability of BayMedica's product portfolio is uncertain due to increased competition and pricing pressures.
• The company's ability to effectively research, develop, manufacture, and commercialize pharmaceutical drug candidates is highly uncertain and subject to numerous risks.
• There is a risk of failure to satisfy Nasdaq listing standards, including compliance with the minimum bid price rule, which could lead to delisting.

Future Outlook

The company expects its cash, cash equivalents, and short-term investments of $9.4 million as of September 30, 2025, to be sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of calendar 2026. This projection is dependent on the level and timing of BayMedica revenues and the company's operating expenses. The company anticipates continued operating losses for the foreseeable future and will need to raise additional capital through equity financings, debt financings, or strategic transactions to finance its operations and achieve business objectives.

Management Comments

• "We expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy."
• "The Commercial segment will continue to evaluate opportunities for potential structured supply arrangements and collaborations for the commercial business."
• "Sales and marketing efforts will remain focused on products that contribute the highest margins, where the Commercial segment continues to hold a strong competitive position."
• "We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued."
• "BayMedica vehemently contests the Licensor's interpretation of the Agreement and its position in the Patent License Matter, and intends to take all necessary steps to vigorously defend the Patent License Matter."

Industry Context

InMed Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sectors, focusing on cannabinoid-based drug development and rare cannabinoid commercialization. The decrease in commercial sales due to increased competition reflects a broader trend of market saturation and pricing pressures in the health and wellness cannabinoid sector. The ongoing R&D efforts in Alzheimer's, dry AMD, and Epidermolysis Bullosa align with significant unmet medical needs, but these areas are also characterized by high development costs, long timelines, and high failure rates, typical for early-stage pharmaceutical companies. The appointment of experienced directors from established biotech and pharma companies suggests an effort to strengthen strategic and financial leadership in a challenging industry landscape.

Comparison to Industry Standards

• The company's accumulated deficit of nearly $119 million and recurring operating losses are common for early-stage pharmaceutical R&D companies, which typically require substantial investment over many years before potential product commercialization.
• The decrease in commercial sales due to pricing pressure is indicative of a maturing and increasingly competitive market for bulk rare cannabinoids, similar to trends seen in other specialized ingredient markets where early movers face erosion of premium pricing as more players enter.
• The ongoing legal dispute regarding royalty payments is a specific company issue, but intellectual property disputes are a common risk in the pharmaceutical and biotech industries, where patent protection and licensing agreements are critical for market exclusivity and revenue generation.
• The company's cash runway into Q4 2026, while providing some liquidity, is relatively short for a pharmaceutical company with multiple drug candidates in preclinical and Phase 2 stages, highlighting the urgent need for additional financing, a common challenge for smaller biotechs compared to larger, revenue-generating peers like Zymeworks Inc. (Mr. Klompas's former company) which successfully scaled to a multi-billion-dollar valuation.

Management Changes

Corporate Governance

Legal Proceedings

• BayMedica, a wholly-owned subsidiary, is involved in an arbitration (Patent License Matter) with a third-party licensor regarding a technology license agreement from February 15, 2021.
• The licensor claims annual royalty payments are guaranteed minimums, seeking approximately US $3.4 million for 2022-2024 and a declaration for approximately $2.3 million in annual minimum payments for the remainder of the agreement term.
• BayMedica disputes the licensor's interpretation and intends to vigorously defend its position.
• An unfavorable outcome could have a material adverse impact on the company's business, financial condition, and BayMedica's ability to continue operations.

Related Party Transactions

• The company has agreements with the University of British Columbia (UBC) for technology assignment and collaborative research, including potential royalty payments to UBC on certain licensing and royalty revenues and a one-time payment upon filing of PCT patent applications.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity financings and potential adverse impact on share price due to the going concern warning, increased net loss, declining commercial sales, and the ongoing legal dispute. The appointment of new directors may offer some long-term strategic benefit.
• **Employees**: The company's financial challenges and need for additional capital could create uncertainty regarding job security and future growth opportunities.
• **Customers (BayMedica)**: May benefit from lower product pricing due to increased competition, but the company's financial instability and legal issues could raise concerns about long-term supply reliability.
• **Creditors**: The going concern warning and accumulated deficit increase the risk profile for existing and potential creditors.
• **Partners/Collaborators**: Potential partners for drug candidates (e.g., INM-755) may view the company's financial position and legal dispute as increased risk, potentially affecting partnership terms or willingness to engage.

Next Steps

• Continue research and development of Product Candidates, including INM-901 (Alzheimer's) and INM-089 (dry AMD).
• Pursue strategic partnership opportunities for INM-755 (Epidermolysis Bullosa) and other itch-related skin conditions.
• Evaluate opportunities for potential structured supply arrangements and collaborations for the BayMedica commercial business.
• Focus sales and marketing efforts on high-margin products within the Commercial segment.
• Seek additional funding through equity financings, debt financings, collaborations, or other strategic transactions to finance operations.
• Vigorously defend BayMedica's position in the Patent License Matter arbitration.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a formal 'going concern' warning, an accumulated deficit of $119 million, and recurring net losses. Commercial sales are declining due to competition, and a significant legal dispute threatens substantial financial liabilities. While there are ongoing R&D programs and new board appointments, the immediate and near-term risks, particularly the liquidity concerns and the potential adverse outcome of the arbitration, outweigh any speculative future upside. Investors should consider divesting to avoid further capital erosion given the high uncertainty and fundamental financial challenges.

Keywords

InMed Pharmaceuticals, BayMedica, 10-Q, Quarterly Report, Biotechnology, Pharmaceuticals, Cannabinoids, Drug Development, Alzheimer's Disease, Epidermolysis Bullosa, Dry AMD, Going Concern, Net Loss, R&D, Clinical Trials, SEC Filing, INM, Nasdaq